Theseus Pharmaceuticals, Inc.

Operating margin

—

Net margin

—

Return on equity

−24.4%

Return on assets

−22.8%

Return on capital (ROCE)

−25.6%

Liabilities / assets

6.7%

Debt / equity

0.07×

Book value / share

$5.36

Revenue growth (YoY)

—

Net income growth (YoY)

—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Accruals / assets

−7.9%clean

Piotroski F-Score

2/6weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Director / officer change · Amended charter or bylaws · Other material eventFeb 14, 2024
• Entered a material agreement · Terminated a material agreement · Director / officer change · Regulation FD disclosureDec 22, 2023
• Director / officer changeDec 4, 2023
• Other material eventNov 27, 2023
• Results of operations · Costs from exit or disposal · Director / officer change · Regulation FD disclosure · Other material eventNov 13, 2023
• Terminated a material agreementOct 31, 2023
• Results of operationsAug 10, 2023
• Results of operations · Regulation FD disclosure · Other material eventJul 13, 2023

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.